Date: 2017-03-23
Type of information: Series A financing round
Company: Syntimmune (USA - MA)
Investors: Apple Tree Partners (USA - NY) Baxalta Ventures (USA - MA) Partners Innovation Fund (USA) additional undisclosed investors
Amount: $26 million
Funding type: series A financing round
Planned used:
- Funds from this tranche of the Series A round will be used to complete the anticipated Phase 1a clinical trial in healthy volunteers of Syntimmune’s lead candidate, SYNT001. The company intends to submit an IND application to the FDA for SYNT001 in mid-2016 to authorize initiation of the Phase 1a study later this year. SYNT001 is a biologic that blocks the FcRn-IgG interaction and is being developed for the treatment of IgG-mediated autoimmune diseases.
Others:
- • On March 23, 2017, Syntimmune announced that it has made important progress by achieving preclinical proof of concept and completing preclinical safety testing, triggering a second tranche of $10 million in its Series A financing, which is expected to total $26 million. The Series A financing is co-led by Apple Tree Partners and Baxalta Ventures, the corporate venture capital arm of Baxalta Incorporated, with participation by the Partners Innovation Fund and additional investors.
Therapeutic area: Autoimmune diseases
Is general: Yes
